Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is projected to issue its Q4 2024 quarterly earnings data before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cardiol Therapeutics Stock Performance
NASDAQ:CRDL traded up $0.02 during mid-day trading on Wednesday, hitting $1.02. The stock had a trading volume of 92,934 shares, compared to its average volume of 382,002. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The company's 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.38. The stock has a market cap of $84.07 million, a price-to-earnings ratio of -2.61 and a beta of 1.00. Cardiol Therapeutics has a twelve month low of $0.77 and a twelve month high of $3.12.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Wednesday, April 16th. Rodman & Renshaw began coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $7.00 target price for the company. Finally, RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Cardiol Therapeutics presently has an average rating of "Buy" and an average price target of $8.40.
View Our Latest Stock Analysis on CRDL
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
